37. 膿疱性乾癬（汎発型） Generalised pustular psoriasis Clinical trials / Disease details

臨床試験数 : 79 / 薬物数 : 57 - (DrugBank : 21) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 102

diseases per page:

Showing 1 to 10 of 79 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05670821 (ClinicalTrials.gov)	April 1, 2023	2/1/2023	PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms	Post-marketing Surveillance of Spesolimab I.V. Infusion in Improvement of Generalized Pustular Psori ...	Generalized Pustular Psoriasis	Drug: Spesolimab	Boehringer Ingelheim	NULL	Not yet recruiting	18 Years	N/A	All	38		Japan
2	NCT05512598 (ClinicalTrials.gov)	November 6, 2022	22/8/2022	HB0034 in Patients With Generalized Pustular Psoriasis (GPP)	Multi-centre, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and E ...	Generalized Pustular Psoriasis	Drug: HB0034	Shanghai Huaota Biopharmaceutical Co., Ltd.	NULL	Recruiting	18 Years	75 Years	All	10	Phase 1	China
3	NCT05366855 (ClinicalTrials.gov)	April 21, 2022	25/4/2022	Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasi ...	A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in ...	Generalized Pustular Psoriasis	Biological: Imsidolimab;Other: Placebo	AnaptysBio, Inc.	NULL	Recruiting	18 Years	80 Years	All	45	Phase 3	United States;Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Morocco;Poland;Romania;Sp ...
4	NCT05352893 (ClinicalTrials.gov)	April 14, 2022	25/4/2022	Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ...	Generalized Pustular Psoriasis	Drug: Imsidolimab high dose;Drug: Imsidolimab low dose;Other: Placebo	AnaptysBio, Inc.	NULL	Recruiting	18 Years	80 Years	All	45	Phase 3	United States;Australia;Georgia;Germany;Korea, Republic of;Malaysia;Morocco;Poland;Romania;Slovakia; ...
5	NCT05239039 (ClinicalTrials.gov)	March 15, 2022	3/2/2022	An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized P ...	Multi-centre, Open-label, Expanded Access Program of 900mg Intravenous (i.v.) Spesolimab in Patients ...	Generalized Pustular Psoriasis	Drug: spesolimab	Boehringer Ingelheim	NULL	Recruiting	18 Years	75 Years	All	50	Phase 3	China
6	JPRN-jRCT2071210127	18/02/2022	23/02/2022	An Expanded Access trial in Japan to provide spesolimab to people with a flare-up in Generalized Pus ...	Multi-centre, open-label, expanded access trial of spesolimab i.v. in patients with generalized pust ...	Generalized Pustular Psoriasis (GPP)	Drug: BI 655130 (Spesolimab) / Solution for infusion	Yamada Nobuko	NULL	Recruiting	>= 20age old	<= 75age old	Both	3	N/A	Japan
7	NCT05200247 (ClinicalTrials.gov)	February 17, 2022	11/1/2022	An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pus ...	Multi-centre, Open-label, Expanded Access Trial of Spesolimab i.v. in Patients With Generalized Pust ...	Generalized Pustular Psoriasis	Drug: spesolimab	Boehringer Ingelheim	NULL	Active, not recruiting	18 Years	75 Years	All	11	Phase 3	Japan
8	EUCTR2021-001447-27-ES (EUCTR)	07/02/2022	12/11/2021	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ...	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ...	Subjects with generalized pustular psoriasis MedDRA version: 20.0;Level: PT;Classification code 1003 ...	Product Code: ANB019 INN or Proposed INN: anti-IL-36R monoclonal antibody	AnaptysBio Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	45	Phase 3	Taiwan;Thailand;Malaysia;Spain;Australia;Georgia;Germany;Korea, Republic of
9	EUCTR2018-003080-56-ES (EUCTR)	07/02/2022	14/12/2021	A 5-year study to test BI 655130 in patients with GeneralizedPustular Psoriasis who took part in pre ...	An open-label, long term extension study to assess the safety andefficacy of BI 655130 treatment in ...	Generalized Pustular Psoriasis MedDRA version: 21.0;Level: LLT;Classification code 10037159;Term: Ps ...	Product Code: BI 655130 INN or Proposed INN: Spesolimab Other descriptive name: MONOCLONAL ANTIBODY AN ...	Boehringer Ingelheim España S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 2	United States;Philippines;Taiwan;Greece;Thailand;Spain;Ukraine;Russian Federation;Chile;Israel;Colom ...
10	EUCTR2021-001448-90-FR (EUCTR)	02/02/2022	05/10/2021	A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in ...	A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in ...	Subjects with generalized pustular psoriasis MedDRA version: 20.0;Level: PT;Classification code 1003 ...	Product Code: ANB019 INN or Proposed INN: anti-IL-36R monoclonal antibody	AnaptysBio Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	45	Phase 3	France;Taiwan;Spain;Malaysia;Thailand;Australia;Georgia;Germany;Korea, Republic of

First Previous1 2 3 4 5…8Next Last